Surgery Alone without Adjuvant Radiation Therapy for High- or Intermediate-Grade Salivary Gland Cancer
ORL · 2025
DOI: 10.1159/000547198 ↗Kurz gefasst
Fachartikel in der Zeitschrift ORL, 2025. Verfasst von Younghac Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Salivary Gland Neoplasms, Carcinoma, Adenoid Cystic. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Postoperative radiation therapy (RT) is recommended for completely resected T1-2 salivary gland cancer (SGC), if the tumor pathology is adenoid cystic carcinoma, intermediate, or high-grade tumors. In this case series, we reviewed cases of intermediate- or high-grade SGC, managed with curative surgery alone without adjuvant RT, and compared those outcomes with pathology- and tumor stage-matched SGC, treated with surgery and postoperative RT.
Methods
We retrieved cases of intermediate- or high-grade tumors arising from the major salivary glands treated with surgery alone without adjuvant RT (N = 29) from the institutional SGC database. The main reasons for no adjuvant RT and treatment outcomes were reviewed in detail. In addition, we established the tumor pathology (grade)- and tumor stage (T1-2N0M0)-matched cases treated with surgery and postoperative RT as comparison groups (N = 59), to investigate relative treatment outcomes.
Results
The overall treatment outcome was 82.7% disease-specific survival (DSS) at a median follow-up of 41 months, with a 10.3% incidence of systemic metastasis in intermediate- or high-grade SGCs treated with surgery alone. The primary reasons for not receiving adjuvant RT were no recommendation by the surgeon (37.9%) and patient refusal of RT (27.6%). Comparisons of the surgery alone and surgery with postoperative RT in tumor pathology (grade)- and tumor stage-matched groups revealed similar treatment outcomes; 100% DSS at 35–50 months in the surgery alone group and 90–100% DSS at 37–60 months in the surgery and postoperative RT group. Meanwhile, patients with advanced SGCs (T3-4 or N+) treated with surgery alone had a DSS of 50.0% at a median follow-up of 63 months, and systemic metastasis was the main cause of treatment failure (37.5%).
Conclusion
Our findings suggest that surgery alone may yield favorable outcomes for a specific subset of early-stage, intermediate- to high-grade SGCs without any adverse pathological features. Further studies are warranted to validate this approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Zitieren
APA
Kim, Y., Kim, H., Choi, N., Kim, E. H., Cho, J., & Jeong, H. S. (2025). Surgery Alone without Adjuvant Radiation Therapy for High- or Intermediate-Grade Salivary Gland Cancer. ORL. https://doi.org/10.1159/000547198
Vancouver
Kim Y, Kim H, Choi N, Kim EH, Cho J, Jeong HS. Surgery Alone without Adjuvant Radiation Therapy for High- or Intermediate-Grade Salivary Gland Cancer. ORL. 2025. doi:10.1159/000547198
BibTeX
@article{Kim2025,
author = {Kim, Younghac and Kim, Hyojun and Choi, Nayeon and Kim, Eun-Hye and Cho, Junhun and Jeong, Han-Sin},
title = {Surgery Alone without Adjuvant Radiation Therapy for High- or Intermediate-Grade Salivary Gland Cancer},
journal = {ORL},
year = {2025},
doi = {10.1159/000547198}
}
EUVIMED